Loading
A phase 1/2 trial of pyrotinib in lung cancer, run by RemeGen Co., Ltd., not yet recruiting.
A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation is a phase 1/2, interventional study registered as NCT05745740 by RemeGen Co., Ltd., with a registry enrolment figure of 26 participants, started 2027-12-01 and due to reach its primary completion in 2027-12-01. Interventions recorded: RC48-ADC; Pyrotinib. Conditions listed: Non-small Cell Lung Cancer. Primary outcome: maximal tolerance dose (MTD) of RC48-ADC combined with Pyrotinib. Lung eligibility wording from the registry: "* According to UICC/AJCC 8th Edition, histologically and/or cytologically-confirmed, cannot be surgically removed, locally advanced or metastatic NSCLC". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares RemeGen, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares HER2-mutant non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/